Transgene Launches TG4070 Trial for Lung Cancer

Transgene has initiated a Phase 1 trial to assess TG4070, their new individualized neoantigen therapeutic vaccine, in conjunction with nivolumab for treating resected non-small cell lung cancer (NSCLC). TG4070 is backed by Transgene's myvac® platform, which incorporates advanced AI tools like SNIPER for high-precision neoantigen selection and scalable cell-line manufacturing.

This novel approach aims to improve the treatment landscape for NSCLC patients post-neoadjuvant therapies, where risk of relapse remains significant. The ongoing development is part of Transgene’s strategy to extend the myvac® platform’s reach to various tumor types, following the success of TG4050 in head and neck cancer.